2025 annual financial data
Ultragenyx Pharmaceutical 2025 Net income growth
Direct answer
Net income growth was -1.02%.
Operating income was -535,000,000 USD and net income was -575,000,000 USD.
Operating cash flow was -466,000,000 USD.
Get free Ultragenyx Pharmaceutical email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 673,000,000 USD
- Operating income
- -535,000,000 USD
- Net income
- -575,000,000 USD
- Operating cash flow
- -466,000,000 USD